Difficulty: Medium
Average Score: 86%
Practice
A patient taking carbamazepine needs to be started on a direct factor Xa inhibitor for antithrombotic therapy. Which of the direct factor Xa inhibitors should be avoided due to drug interactions?
Correct answer
C
Rationale
In this scenario, the correct answer is C) Rivaroxaban. When a patient is taking carbamazepine, it induces the metabolism of many drugs via the cytochrome P450 enzyme system. Rivaroxaban is metabolized by both CYP3A4 and CYP2J2 enzymes, and carbamazepine is a potent inducer of CYP3A4. This interaction can significantly reduce the plasma levels of rivaroxaban, leading to decreased efficacy of the antithrombotic therapy.
Option A) Betrixaban, Option B) Apixaban, and Option D) Edoxaban are not primarily metabolized by CYP3A4 and are not significantly affected by carbamazepine-induced enzyme activity. Therefore, they would be more suitable choices for antithrombotic therapy in a patient taking carbamazepine.
Educationally, understanding drug interactions is crucial for healthcare providers to ensure safe and effective treatment for patients. Knowledge of how certain drugs affect the metabolism of others can help in making informed decisions when selecting medications, preventing potential adverse effects or treatment failures. It highlights the importance of individualizing therapy based on a patient's specific clinical profile and medication regimen.
Option A) Betrixaban, Option B) Apixaban, and Option D) Edoxaban are not primarily metabolized by CYP3A4 and are not significantly affected by carbamazepine-induced enzyme activity. Therefore, they would be more suitable choices for antithrombotic therapy in a patient taking carbamazepine.
Educationally, understanding drug interactions is crucial for healthcare providers to ensure safe and effective treatment for patients. Knowledge of how certain drugs affect the metabolism of others can help in making informed decisions when selecting medications, preventing potential adverse effects or treatment failures. It highlights the importance of individualizing therapy based on a patient's specific clinical profile and medication regimen.